Press Releases

AVS Raises $20 Million in Series B Round to Advance Pulsatile Intravascular Lithotripsy (PIVL) Solutions

BOSTON--(BUSINESS WIRE)--AVS, an early-stage medical device company focused on safely and effectively treating severely calcified arterial disease with its PIVL™ therapy, announced today that it raised $20 million in Series B financing. The new funding will accelerate clinical trial timelines for the company’s device for peripheral application in pulsatile intravascular lithotripsy (PIVL) cases and advance development and preclinical work on a PIVL device for coronary cases.

AVS Announces Multi-Site Enrollment of First Patients in POWER PAD I Clinical Trial and Appointment of William H. Kucheman to Board of Directors

Pulsatile Intravascular Lithotripsy shows promise as new treatment therapy for severely calcified vessels

ANN ARBOR, Mich. – September 15, 2022, -- AVS, an early-stage medical device company focused on safely and effectively treating severely calcified arterial disease with its PIVL™ therapy, today announced enrollment, successful treatment, and positive 30-day follow up data of the first patients in the POWER PAD I clinical trial. AVS is only the second company to conduct a first-in-human study in the rapidly growing intravascular lithotripsy space.

In The News